Printer Friendly

ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES APPOINTMENT OF NEW GENERAL MANAGER OF CANADIAN SUBSIDIARY

 EATONTOWN, N.J., June 15 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) today announced the appointment of Mr. Arthur Woodruff as the new general manager for its Canadian subsidiary, Roberts Pharmaceutical of Canada, Inc. In his new position, Mr. Woodruff will assume full management responsibility for Roberts Pharmaceutical of Canada and will play a key role in the continued growth and development of Roberts Canadian subsidiary.
 Mr. Woodruff joins Roberts with 29 years of professional pharmaceutical experience with specific responsibilities in marketing, sales and business development. Most recently, Mr. Woodruff held the position of Vice-President, Promocare Resources, Inc. Prior to this, Mr. Woodruff held various senior level positions with American Home Products, Glaxo Canada Inc. and Merck Frosst Canada Inc. In addition to his professional experiences, Mr. Woodruff is a graduate of the University of British Columbia. He and his family reside in Downsview, Ontario.
 Roberts Pharmaceutical of Canada is a wholly owned subsidiary of Roberts Pharmaceutical Corporation. Roberts of Canada currently markets and distributes a line of prescription products that include DUVOID, RIMSO-50, NORPACE, PROBANTHINE, BETNESOL, TRANDATE, and the nonprescription products GLAXAL BASE, BARRIERE and PRENAVITE.
 Roberts Pharmaceutical is an international pharmaceutical company focusing on the acquisition and development of high-potential, undervalued, late-stage development products and the acquisition of currently marketed prescription and nonprescription products. Roberts products are currently marketed in seven countries with operating subsidiary companies in the U.S., Canada, and the United Kingdom. Roberts has seven drugs in late stage clinical development and currently markets over 100 different products for urological therapy, pain management, cough/cold, gastrointestinal disease, endocrine disorders and dermatological conditions.
 -0- 6/15/93
 /CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
 (RPCX)


CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU: PER

TS -- NY017 -- 2017 06/15/93 10:14 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 15, 1993
Words:299
Previous Article:RAYOVAC INTRODUCES REUSABLE ALKALINE SYSTEM
Next Article:UNITED ASSET MANAGEMENT CORPORATION DECLARES QUARTERLY DIVIDEND
Topics:


Related Articles
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES APPOINTMENT OF CHIEF OPERATING OFFICER
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES APPOINTMENT OF CHIEF OPERATING OFFICER
ROBERTS PHARMACEUTICAL CORPORATION ELECTS NEW DIRECTOR
ROBERTS PHARMACEUTICAL CORPORATION APPOINTS VICE PRESIDENT, DEVELOPMENTAL THERAPEUTICS
CYTRX CORPORATION ANNOUNCES APPOINTMENT OF PRESIDENT AND CEO OF VAXCEL, INC.
CYTRX CORPORATION ANNOUNCES APPOINTMENT OF PRESIDENT AND CEO OF VAXCEL, INC.
ROBERTS PHARMACEUTICAL CORPORATION EXPANDS EUROPEAN OPERATIONS BY ESTABLISHMENT OF FRENCH SUBSIDIARY - APPOINTS MANAGING DIRECTOR
SCHERING-PLOUGH APPOINTS STOUT PRESIDENT, SCHERING LABORATORIES
CLOSING COMPLETED, SANOFI NAMES MANAGEMENT TEAM FOR PHARMACEUTICAL DIVISION
ROBERTS PHARMACEUTICAL CORPORATION CREATES THE POSITION OF WORLDWIDE SALES AND MARKETING AND ANNOUNCES MANAGEMENT ADDITIONS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters